Immunocore to present at upcoming investor conferences

Rhea-AI Summary

Immunocore Holdings (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines, has announced its participation in two upcoming investor conferences. The company will present at the Guggenheim Securities Healthcare Innovation Conference on Tuesday, November 12, 2024, at 1:00 p.m. EST, and the Jefferies London Healthcare Conference on Wednesday, November 21, 2024, at 9:00 a.m. GMT.

Both presentations will be available via webcast on Immunocore's website in the 'Events & Presentations' section, with replays available for a time after the events.

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.

                  Guggenheim Securities Healthcare Innovation Conference
                  Fireside Chat: Tuesday, November 12, 2024, at 1:00 p.m. EST

                  Jefferies London Healthcare Conference
                  Fireside Chat: Wednesday, November 21, 2024, at 9:00 a.m. GMT

The presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Investor Relations

Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com

FAQ

When is Immunocore (IMCR) presenting at the Guggenheim Securities Healthcare Conference in 2024?

Immunocore (IMCR) will present at the Guggenheim Securities Healthcare Innovation Conference on Tuesday, November 12, 2024, at 1:00 p.m. EST.

What time is Immunocore's (IMCR) presentation at the Jefferies London Healthcare Conference?

Immunocore (IMCR) will present at the Jefferies London Healthcare Conference on Wednesday, November 21, 2024, at 9:00 a.m. GMT.

Where can I watch Immunocore's (IMCR) investor conference presentations?

The presentations can be accessed through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website at www.immunocore.com.